Abstract: The present invention is related to derivatives of benzenesulfonamide represented by formula (I), and the pharmaceutical composition thereof. In addition, the benzenesulfonamide derivatives disclosed in the present invention can serve as potential cell cycle inhibitors, and thereby these benzenesulfonamide derivatives and the pharmaceutical composition thereof can be antitumor drug candidates, which might aim at cell cycle. Particularly, the benzenesulfonamide derivatives disclosed in the present invention may function as antitumor drugs to treat solid cancers.

Abstract: The present invention is related to derivatives of benzenesulfonamide represented by formula (I), and the pharmaceutical composition thereof. In addition, the benzenesulfonamide derivatives disclosed in the present invention can serve as potential cell cycle inhibitors, and thereby these benzenesulfonamide derivatives and the pharmaceutical composition thereof can be antitumor drug candidates, which might aim at cell cycle. Particularly, the benzenesulfonamide derivatives disclosed in the present invention may function as antitumor drugs to treat solid cancers.

Abstract: An ultrasonic nebulizer for producing high-volume sub-micron droplets is disclosed. The ultrasonic nebulizer utilizes a 3 or 5 MHz frequency as an oscillation frequency for producing sub-micron droplets. The nebulizer can also use at least one piezoelectric ceramic oscillator for increasing the volume of the droplets. The ultrasonic nebulizer comprises an ac/dc converter, an oscillator circuit, an amplifying device, a nebulization chamber, and at least one piezoelectric ceramic oscillator. The ac/dc converter rectifies an ac current to a dc current. The oscillator circuit produces an oscillation signal with a frequency larger than or equal to 3 MHz. The amplifying device amplifies the oscillation signal. The nebulization chamber has a lower face for holding a liquid to be nebulized.

Abstract: This invention relates to cyclic peptides, with the following formula (I) (SEQ ID NO: 1), cyclo(Xaa-Arg-Pro-Ala-Lys)??(I) where Xaa is Ala, Gly, Glu, Gln, Asp, Asn, Arg or Lys. The cyclic peptides have thrombolytic effects. This invention also relates to cyclic peptide preparations.

Abstract: A method for preparing porous bioceramic bone substitute materials is disclosed, which includes the following steps: (a) providing a cancellous bone of animals, (b) removing organic substances in the cancellous bone by thermal processing to obtain de-organic cancellous bone, (c) soaking the de-organic cancellous bone in a solution of phosphate salts, and (d) obtaining the porous bioceramic materials by sintering between 600 to 900° C. The porous bioceramic bone substitute materials of the present invention are suitable for use as filling materials of bone defect.

Abstract: An ultrasonic nebulizer for producing high-volume sub-micron droplets is disclosed. The ultrasonic nebulizer utilizes a 3 or 5 MHz frequency as an oscillation frequency for producing sub-micron droplets. The nebulizer can also use at least one piezoelectric ceramic oscillator for increasing the volume of the droplets. The ultrasonic nebulizer comprises an ac/dc converter, an oscillator circuit, an amplifying device, a nebulization chamber, and at least one piezoelectric ceramic oscillator. The ac/dc converter rectifies an ac current to a dc current. The oscillator circuit produces an oscillation signal with a frequency larger than or equal to 3 MHz. The amplifying device amplifies the oscillation signal. The nebulization chamber has a lower face for holding a liquid to be nebulized.

Abstract: A biodegradable ceramic for medical use is disclosed, which comprises calcium hydrogenphosphate (CaHPO4) modified by organic molecules. The organic molecule mentioned above is hexamethylene diisocyanate (HMDI), which is grafted to the calcium hydrogenphosphate through covalent bond. The present invention also relates to a method for preparing the biodegradable ceramics. In addition, the biodegradable ceramic can be used for repair of bone defects. Therefore, the present invention further relates to a method and a device for repair of bone defects, and to a delivery system for the medicine of repair of bone defects.

Abstract: This invention relates to cyclic peptides, with the following formula (I) (SEQ ID NO: 1),

Abstract: The present invention relates to a method for transferring one or more active ingredients between different phase carriers, which includes: (a) providing a solid, semi-solid, or nonaqueous liquid drug which contains at least one active ingredient; (b) admixing said drug with water or water solution to form an admixture; and (c) nebulizing said admixture to form liquid fine drops containing said active ingredient. This method enables the active ingredient stored in a solid phase carrier to transfer into an aqueous phase carrier, or enables the active ingredient stored in a non-aqueous liquid carrier to transfer into an aqueous phase carrier. The aqueous phase carrier contains the active ingredient can then be nebulized with a nebulizer by means of ultrasonic vibration. The present invention provides a new method for controlling administration by transferring the active ingredient between different phase carriers.

Abstract: A biphasic cement of &agr;-TCP/HAP is primarily composed of 30-60 wt % &agr;-tricalcium phosphate (Ca3(PO4)2, &agr;-TCP) and 40-70 wt % of hydroxyapatite (Ca10(PO4)6(OH)2, HAP). The biphasic cement of &agr;-TCP/HAP of the present invention is superior since it can set rapidly while soaking in a water solution. The present invention also provides a process for preparing the biphasic cement of &agr;-TCP/HAP, in which the composition of the biphasic cement of &agr;-TCP/HAP can be controlled.

Abstract: A bone substitute comprises gelatin powder, water, tricalcium phosphate (TCP) powder, and glutaraldehyde. The bone substitute in the present invention, using tricalcium phosphate powder as the major implant ingredient, gelatin powder as glue, and glutaraldehyde as cross-linking agent, can reduce the degradation rate of the bone substitute in the biological body. The present invention also includes the manufacturing procedure of the bone substitute.

Abstract: A process for preparing porous bioceramic materials includes the following steps: (a) using the cancellous bone of animals, (b) removing organic substances in the cancellous bone by thermal processing to obtain de-organic cancellous bone, (c) soaking the de-organic cancellous bone in a solution of phosphate salts, and (d) obtaining porous bioceramic materials by sintering up to 900.degree. C. or higher after dehydration. The porous bioceramic materials of the present invention are suitable for use as filling materials for bone defect.

Abstract: A process for preparing a well crystallized alkali metal salt of 3, 7-substituted 7-aminocephalosporanic acid derivatives having the general formula: ##STR1## wherein: R1= ##STR2## R.sup.2 =CH3 or C1 M=Na or Kfrom the acid-form derivatives. The process includes preparing a 30% suspension by weight of the acid-form derivative in concentrate alcohol containing 3 to 7% of water by weight, and add an alcoholic solution of alkali base to the suspension under room temperature. The alcohol used to dissolve the base also contains 3 to 7% of water. After a reaction time of 5 to 20 minutes, cool the mixture and let the salt crystallize, and separate the latter from the liquid phase.